Although several effective anti-inflammatory agents and bronchodilators are currently available for controlling disease in mild asthmatics, unmet needs exist in treating moderate to severe disease. According to the insights of surveyed U.S. and European pulmonologists, greater reduction in exacerbation rate and greater improvement in quality of life are key areas of unmet need for moderate to severe asthma. Furthermore, novel agents with strong efficacy in reducing the rate of exacerbations will have considerable influence on physician prescribing decisions as competition among pharmacological agents rapidly increases in the moderate to severe asthma market.

Related Reports

Asthma - Current Treatment - Detailed, Expanded Analysis (EU5)

The asthma market in the EU5 is highly competitive. Ma...

View Details

Asthma - Landscape & Forecast - Disease Landscape & Forecast

The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s...

View Details

Asthma - Unmet Need - Detailed, Expanded Analysis (Severe Asthma)

Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the entry of

View Details

Asthma - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Adult Asthma (US)

Adult asthma is treated using two types of pharmacotherapy: rescue therapy to treat acute symptoms via bronchodilation (e.g., a SABA) and maintenance therapy to prevent exacerbations by targeting u...

View Details